Integration of Novel Immunotherapies
into
the Paradigm of MSI-positive mCRC
A continuing medical education activity sponsored by NAMCP and AAMCN.
New Horizons in the Treatment and
Management of Metastatic Colorectal Cancer (mCRC): Best Practices
for Improved Patient Outcomes is a multi-part series that will
provide participants with the latest information on Metastatic
Colorectal Cancer
This is Part II of the series focusing on Integration of Novel
Immunotherapies
into the Paradigm of MSI-positive mCRC
This activity is an archive from the webinar held July 28, 2017. If
you participated in the live webinar,
you are not eligible for credits for this activity.
This activity is valid from September 1, 2017 to September 30, 2018 |
Instructions for CME/CNE: Complete the pre test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. If you close your internet browser without
completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to
receive continuing education credits. If you do not pass the post
test after two attempts, you will not be eligible to try again. Once
you complete the evaluation form and score 70% or higher on your
post test, you will automatically be given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
Bayer Healthcare Pharmaceuticals and Merck Sharp & Dohme Corp
Description:
Colorectal cancer (CRC) is the development of cancer from the colon
or rectum, due to the abnormal growth of cells that have the ability
to invade or spread to other parts of the body. Excluding skin
cancers, colorectal cancer is the third most common cancer diagnosed
in both men and women in the United States. In 2017, it is expected
that there will be 134,490 new cases of colorectal cancer and 49,190
deaths. When discovered early, CRC is highly treatable. However,
when the disease has spread, or metastasized, treatment and
management becomes much more difficult. Fortunately, targeted- and
immuno-therapy options have become available for patients with
metastatic colorectal cancer (mCRC), giving clinicians and managed
care professionals more options in managing this patient population.
This is part 2 of a five-part webinar series that will look closely
at the use of immunotherapies in MSI-positive mCRC.
Upon Completion of this
activity, participants will be able to:
-
Discuss the role of immunotherapies
in the treatment of MSI-positive mCRC
-
Review recent clinical data on
immunotherapy in the management of MSI-positive mCRC
-
Individualize treatment with
immunotherapeutic agents based on patient factors including
tumor characteristics, treatment history, common adverse
effects, and age for optimal care
-
Assess key sequencing considerations
when formulating a plan for individualized treatment in MSI-positive
mCRC
Faculty: |
Gerard Blobe, M.D.,
Ph.D.
Department of Medicine
Department of Pharmacology and Cancer Biology
Duke University Medical Center |
Disclosure:
|
Dr. Blobe
serves as on the speaker’s bureau to Genentech/Roche;
serves as a consultant for Genentech/Roche and has
received income in any amount from Genentech/Roche. His
presentation has been peer reviewed for any bias.
|
|
Planning Committee:
Bill Williams, MD has no real or perceived financial
relationships to disclose.
Will Williams has no real or perceived financial
relationships to disclose.
Jacquelyn Smith has no real or perceived financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
nursing credit.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This presentation
is
supported by educational grants from
Bayer Healthcare Pharmaceuticals and Merck Sharp & Dohme Corp
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |